Regarding “Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion”  by Comerota, Anthony J.
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February 2011562 Letters to the Editorcross over from no treatment to treatment was either aneurysm
becoming symptomatic, a very subjective event, or the patients’
request for treatment because of concerns related to their aneu-
rysm. Very few patients, in all of the trials cited, crossed over from
no treatment to treatment because of aneurysm size increases,
which exceeded the limits defined in the protocols. Subjective,
rather than objective, reasons for changing a randomized treat-
ment assignment can undermine, to some degree, the validity of
the trial.
While we appreciate the comments made to the editors reflect-
ing a need to defend the particular trial cited, we note that the
authors’ conclusions are even more sweeping than ours. We do not
claim that this problem is “universal” with, or that it negates the
conclusions of, all randomized trials of such design. We simply
reported that a crossover from no treatment to treatment was a
problem in the author’s experience with the PIVOTAL (Positive
Impact of Endovascular Options for Treating Aneurysms Early)
trial. In reviewing other trials of the same design, we found similar
problems in the examples cited, (ie, in which AAA intervention was
pitted against no treatment) the conclusions of such trials were
jeopardized, if not made controversial, by the significant crossover
rate. We are in no way generalizing or implying that randomized
trials are not the “gold standard” of level I evidence, as the Letter
to the Editor implies.
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Regarding “Endovenectomy of the common femoral
vein and intraoperative iliac vein recanalization for
chronic iliofemoral venous occlusion”
I recently had the privilege of reporting “Endovenectomy of
the common femoral vein and intraoperative iliac vein recanaliza-
tion for chronic iliofemoral venous occlusion”1 in a patient with
debilitating, chronic, postthrombotic occlusion of his iliofemoral
venous system. The article stated that this was the first report of
endovenectomy with endoluminal recanalization for patients such
as these.
Although this is a true statement regarding the peer-reviewed
literature, I saw this week that Dr Peter Gloviczki reported this
procedure in the fifth edition of Rutherford’s Vascular Surgery
textbook.2 I was not aware of his description in Vascular Surgery at
the time the article was written. Dr Gloviczki discussed this tech-
nique with me approximately 2 years ago, which stimulated the
team at the Jobst Vascular Center to pursue this treatment option
in patients with chronic, postthrombotic, iliofemoral venous
obstruction.
I want to recognize this important contribution of Dr
Gloviczki and his team at Mayo Clinic as being the catalyst for our
embarking on this technique and recognize that they were the first
to publish this concept. Thank you, Peter!
c
wnthony J. Comerota, MD
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egarding “Causes of late mortality after
ndovascular and open surgical repair of infrarenal
bdominal aortic aneurysms”
We read with great interest a large (13,971 patients) retro-
pective cohort study by Goodney et al1 of patients undergoing
ndovascular (EVAR) and open surgical repair (OSR) of abdomi-
al aortic aneurysm. As expected, early mortality occurred in
atients undergoing OSR, whereas deaths in patients undergoing
VAR occurred later. Although overall long-term mortality was
imilar in both cohorts (15.3% for EVAR and 15.9% for OSR at a
edian follow-up of 1.6 and 1.9 years, respectively), with an
djusted hazard ratio for mortality for patients undergoing EVAR
f 0.98 (95% confidence interval, 0.90-1.07), the two unadjusted
urvival curves crossed at approximately 1.6 years of follow-up. A
ossible explanation could be that patients undergoing EVAR have
ore comorbidity and thus may be more likely to die after dis-
harge than patients undergoing OSR.
To confirm whether crossing of survival curves occurs also in
andomized cohorts (equal-risk patients), we performed a meta-
nalysis of three well-known trials: Endovascular Aneurysm Repair
,2 Dutch Randomized Endovascular Aneurysm Management,3
nd Open Versus Endovascular Repair.4 The pooled cumulative
urvival rates were yielded by means of a strategy to combine
urvival data constructed by Pereira et al.5
In the first step, we redistributed in equal quantities at
-month intervals patients censored at intervals 1 month. Next,
e obtained the numbers of deaths for intervals of 1 month by
sing the patients at risk at the start of an interval, the redistributed
ensored patients, and the interval survival rates. We then calcu-
ated the Kaplan-Meier survival rates for each trial and each month
f follow-up and used these rates as treatment effects.
In the second step, we calculated a within-trials variance for
ach monthly survival rate in each trial; next, we calculated a
etween-trials variance for each month. To obtain pooled mea-
ures of treatment effect for each month of follow-up, we used in
he third step random-effects modeling.
Finally, the product of successive monthly pooled measures of
reatment effect allowed us to obtain pooled measures of cumula-
ive survival.
The pooled cumulative survival rates of EVAR and OSR were,
espectively, 97.8% and 94.4% at 1 month; 95.3% and 92.2% at 1
ear; 90.1% and 88.6% at 2 years; 82.8% and 83.4% at 3 years;
7.5% and 79.2% at 4 years; and 74.2% and 76.3% at 5 years
Fig). Two survival curves crossed at approximately 2.7 years of
ollow-up.
The results of our analysis suggest that crossing of survival
urves of EVAR and OSR occurs even in randomized cohorts
hough the intersection is delayed by approximately one year as
ompared with the retrospective cohorts in the study by Goodney
t al.1 To confirm whether the differences in mortality after the
rossing are increased, longer-term results of randomized trials
ould be needed.
